HK1209104A1 - 抑制劑 - Google Patents

抑制劑

Info

Publication number
HK1209104A1
HK1209104A1 HK15109686.3A HK15109686A HK1209104A1 HK 1209104 A1 HK1209104 A1 HK 1209104A1 HK 15109686 A HK15109686 A HK 15109686A HK 1209104 A1 HK1209104 A1 HK 1209104A1
Authority
HK
Hong Kong
Prior art keywords
vegfr3
inhibitors
vegfr3 inhibitors
inhibitors vegfr3
Prior art date
Application number
HK15109686.3A
Other languages
English (en)
Inventor
Richard Charles Foitzik
Neil Choi
Benjamin Joseph Morrow
Catherine Fae Hemley
Gillian Elizabeth Lunniss
Michelle Ang Camerino
Danny Ganame
Paul Anthony Stupple
Romina Lessene
Wilhelmus Johannes Antonius Kersten
Andrew John Harvey
Ian Peter Holmes
Original Assignee
Cancer Therapeutics Crc Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Therapeutics Crc Pty Ltd filed Critical Cancer Therapeutics Crc Pty Ltd
Publication of HK1209104A1 publication Critical patent/HK1209104A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15109686.3A 2012-08-17 2015-10-02 抑制劑 HK1209104A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261684254P 2012-08-17 2012-08-17
PCT/AU2013/000912 WO2014026242A1 (en) 2012-08-17 2013-08-16 Vegfr3 inhibitors

Publications (1)

Publication Number Publication Date
HK1209104A1 true HK1209104A1 (zh) 2016-03-24

Family

ID=50101125

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109686.3A HK1209104A1 (zh) 2012-08-17 2015-10-02 抑制劑

Country Status (8)

Country Link
US (2) US20150225377A1 (zh)
EP (1) EP2885292A4 (zh)
JP (1) JP2015524825A (zh)
CN (2) CN104837835A (zh)
AU (1) AU2013302319A1 (zh)
CA (1) CA2882270A1 (zh)
HK (1) HK1209104A1 (zh)
WO (1) WO2014026242A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015123722A1 (en) * 2014-02-19 2015-08-27 Bionomics Limited Inhibitors
JP2019505498A (ja) 2015-12-16 2019-02-28 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害
EP4026849A1 (en) * 2016-09-26 2022-07-13 Ensemble Group Holdings Methods of assessing and treating cancer in subjects having dysregulated lymphatic systems using a combination of vegfr-3 and pd-1 or pd-l1 inhibitors
CN118059233A (zh) 2016-10-27 2024-05-24 加利福尼亚大学董事会 整合素α9的阻断抑制淋巴管瓣形成并促进移植物存活
US10954216B2 (en) 2016-12-27 2021-03-23 Riken BMP-signal-inhibiting compound
CN109942616A (zh) * 2019-04-18 2019-06-28 广东工业大学 一种含炔基的芳基酰胺类衍生物及其制备方法和应用
CN114853740B (zh) * 2021-02-03 2023-08-01 药雅科技(上海)有限公司 炔类嘧啶化合物作为fgfr抑制剂的制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1438053E (pt) 2001-10-17 2008-09-25 Boehringer Ingelheim Int Derivados de pirimidina, medicamento contendo estes compostos, sua utilização e processo para a sua preparação
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
BRPI0921317A2 (pt) 2008-11-06 2017-06-06 Astrazeneca Ab composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BRPI0921392A2 (pt) * 2008-12-05 2016-04-26 Abbott Lab inibidores quinase com perfil de segurança cyp aperfeiçoado
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
JP2012526766A (ja) * 2009-05-14 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍性及び線維性疾患の処置における新規な併用療法
DE102010034699A1 (de) 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
EP2616057A4 (en) * 2010-09-14 2014-03-12 Glaxosmithkline Ip No 2 Ltd COMBINATION OF B-RAF AND VEGFR INHIBITORS
AU2012216893B2 (en) 2011-02-17 2016-08-11 Cancer Therapeutics Crc Pty Limited FAK inhibitors
ES2724525T3 (es) 2011-02-17 2019-09-11 Cancer Therapeutics Crc Pty Ltd Inhibidores selectivos de FAK
KR101682417B1 (ko) 2011-02-25 2016-12-06 주식회사유한양행 다이아미노피리미딘 유도체 및 그의 제조방법
AU2013292054B2 (en) 2012-07-17 2017-08-03 Sanofi Use of VEGFR-3 inhibitors for treating hepatocellular carcinoma
WO2014027199A1 (en) * 2012-08-14 2014-02-20 Cancer Therapeutics Crc Pty Ltd Fak and flt3 inhibitors
WO2014026243A1 (en) 2012-08-17 2014-02-20 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
CN103113355B (zh) 2013-02-27 2014-08-13 无锡爱内特生物科技有限公司 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用

Also Published As

Publication number Publication date
EP2885292A1 (en) 2015-06-24
CN104837835A (zh) 2015-08-12
CN106986832A (zh) 2017-07-28
US9266864B2 (en) 2016-02-23
AU2013302319A1 (en) 2015-02-26
JP2015524825A (ja) 2015-08-27
US20150225377A1 (en) 2015-08-13
EP2885292A4 (en) 2015-07-01
WO2014026242A1 (en) 2014-02-20
US20140080798A1 (en) 2014-03-20
CA2882270A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
ZA201504200B (en) Beta-lactamase inhibitors
IL237011A0 (en) Dihydropyridone p1 as factor xia inhibitors
HK1208363A1 (zh) 新方法
IL237012A0 (en) Dihydropyridone p1 as factor xia inhibitors
HK1248702A1 (zh) 取代的吡咯烷-2-甲酰胺
HK1200830A1 (zh) 取代的吡咯烷- -甲酰胺
HK1207366A1 (zh) 作為 抑制劑的塞二唑啉酮二酮
GB201211310D0 (en) CSF-1R kinase inhibitors
HK1206724A1 (zh) 取代的苯並噻吩並嘧啶
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
HK1209105A1 (zh) 抑制劑
HK1209104A1 (zh) 抑制劑
HK1209422A1 (zh) 抑制劑
EP2934541A4 (en) NORIBOGAINE SUBSTITUTE
HK1206022A1 (zh) 取代的咪唑並噠嗪
EP2847201A4 (en) 6-oxo-purin-phosphoribosyl INHIBITORS
HK1212895A1 (zh) 用於免疫調節的沙奎那韋-
GB201213825D0 (en) Damper-device for bouncing-device